急诊科连续心电监测对心房颤动的机会性筛查
该回顾性队列研究纳入2020年8月23日至2024年1月16日期间在学术型急诊科接受连续心电监测的65,244例连续成人患者。主要结局为监测到至少30秒心房颤动且出院时未记录心房颤动诊断或未抗凝的患者比例。结果显示1,945例(3.0%)出院时存在未诊断心房颤动,其中1,385例(71.2%)符合抗凝标准。与监测无心房颤动患者相比,未诊断心房颤动患者调整后卒中风险比为3.00(95%CI 2.39-3.76);与已知心房颤动患者相比为1.32(95%CI 1.02-1.71)。作者认为急诊机会性筛查可能有助于早期诊断和抗凝以预防卒中。
要点
- 急诊连续心电监测的65,244例成人患者中,1,945例(3.0%)出院时存在未诊断心房颤动,其中1,385例(71.2%)符合抗凝标准。
- 未诊断心房颤动患者较已知心房颤动患者更年轻(中位年龄72岁 vs 79岁)、女性更多(49.6% vs 43.7%)、医疗补助比例更高(16.9% vs 7.0%)、缺乏初级保健提供者比例更高(22.5% vs 12.4%)。
- 未诊断心房颤动患者随访期间卒中发生率为2.6例/100人年,调整后卒中风险比对比监测无心房颤动患者为3.00(95%CI 2.39-3.76),对比已知心房颤动患者为1.32(95%CI 1.02-1.71)。
- 未诊断心房颤动患者中黑种人(7.0% vs 3.7%)和西班牙裔/拉丁裔(17.1% vs 9.5%)比例高于已知心房颤动患者。
- 作者认为急诊机会性筛查可能有助于早期诊断和抗凝以预防卒中。
适用人群与场景
- 2020年8月23日至2024年1月16日在学术型急诊科接受连续心电监测的65,244例连续成人患者。
诊断标准与关键阈值
- 未诊断心房颤动定义为连续监测到至少30秒心房颤动且出院时未记录心房颤动诊断或未抗凝。
- 符合抗凝标准基于CHA2DS2-VASc评分。
研究设计与关键结果
- 回顾性队列研究,纳入65,244例连续成人患者,主要终点为出院时未诊断心房颤动比例。
- 1,945例(3.0%)出院时存在未诊断心房颤动,其中1,385例(71.2%)符合抗凝标准。
- 未诊断心房颤动患者中位年龄72岁(四分位距50-84),已知心房颤动患者79岁(四分位距69-87)。
- 未诊断心房颤动患者女性占49.6%,已知心房颤动患者女性占43.7%。
- 未诊断心房颤动患者医疗补助占16.9%,已知心房颤动患者占7.0%;缺乏初级保健提供者占22.5% vs 12.4%;黑种人占7.0% vs 3.7%;西班牙裔/拉丁裔占17.1% vs 9.5%。
- 未诊断心房颤动患者卒中发生率为2.6例/100人年,调整后卒中风险比对比监测无心房颤动患者为3.00(95%CI 2.39-3.76),对比已知心房颤动患者为1.32(95%CI 1.02-1.71)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为急诊机会性筛查可能有助于早期诊断和抗凝以预防卒中。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVES: To determine the prevalence of undiagnosed atrial fibrillation detectable through continuous ECG monitoring in adult emergency department (ED) patients, and to estimate the stroke risk of ED patients discharged with undiagnosed atrial fibrillation.
METHODS: Retrospective cohort study of 65,244 unique consecutive adult patients who received continuous ECG monitoring in an academic ED from August 23, 2020, to January 16, 2024. Primary outcome was the proportion of patients with at least 30 seconds of atrial fibrillation on continuous monitoring who were discharged without documented atrial fibrillation diagnosis or anticoagulation. Secondary outcomes included atrial fibrillation burden, proportion of cases suitable for anticoagulation based on CHA2DS2-VASc score, and incidence of ischemic stroke through August 31, 2024, by atrial fibrillation status on discharge (no atrial fibrillation, known atrial fibrillation, and undiagnosed atrial fibrillation). We compared demographic and insurance characteristics of patients with undiagnosed versus known atrial fibrillation. We estimated Cox proportional hazard models for ischemic stroke after ED visit, stratified by atrial fibrillation status and adjusting for CHA2DS2-VASc score.
RESULTS: Of 65,244 monitored patients, 1,945 (3.0%) were discharged with undiagnosed atrial fibrillation, with 1,385 (71.2%) meeting criteria for anticoagulation. Compared to patients with known atrial fibrillation, patients with undiagnosed atrial fibrillation were younger (median age 72 [interquartile range, 50 to 84] versus 79 [interquartile range, 69 to 87] years), more likely to be women (49.6% versus 43.7%), on Medicaid (16.9% versus 7.0%), lack a primary care provider (22.5% versus 12.4%), and identify as Black (7.0% versus 3.7%) or Hispanic/Latino (17.1% versus 9.5%). Patients with undiagnosed atrial fibrillation had 2.6 ischemic strokes per 100 person-years of follow-up, with an adjusted hazard ratio for stroke of 3.00 (95% confidence interval, 2.39 to 3.76) compared to patients without atrial fibrillation on monitor, and 1.32 (95% confidence interval, 1.02 to 1.71) compared to patients with known atrial fibrillation.
CONCLUSION: Analysis of continuous ECG monitoring in the ED identified undiagnosed atrial fibrillation in 3% of patients, predominantly from underserved populations, and at high risk of stroke. Opportunistic screening in the ED could facilitate earlier diagnosis and anticoagulation to prevent stroke.
参考来源
- Bismuth E, Jin BT, Molins E, et al. Opportunistic Screening for Atrial Fibrillation With Continuous ECG Monitoring in the Emergency Department. Ann Emerg Med. 2025. PMID: 40650644. doi:10.1016/j.annemergmed.2025.06.008
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。